Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials
Vascular Pharmacology · 2025
DOI: 10.1016/j.vph.2025.107520 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Vascular Pharmacology, 2025. Verfasst von Mohammad Abdulelah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Massachusetts Chan Medical School, Baystate Medical Center, Springfield, MA 01199, USA. Electronic add…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Arterial Pressure, Pulmonary Arterial Hypertension, Pulmonary Artery. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Pulmonary arterial hypertension (PAH) remains a life-threatening condition characterized by high morbidity and mortality. However, recent therapeutic advancements have offered a paradigm shift in terms of therapeutic goals. METHODS: We conducted a systematic review and meta-analysis of RCTs assessing clinical outcomes and safety of sotatercept when compared to placebo in PAH. Searches of Pubmed and Cochrane Central databases were performed through April 2025. The primary outcome was all-cause mortality. Secondary outcomes included improvements in 6MWD, WHO functional class, hemodynamics, NT-proBNP, and serious adverse events. Data were pooled using a random-effects model, with certainty of evidence assessed via GRADE methodology. RESULTS: Three RCTs comprising 601 patients were included. There was a non-significant trend toward reduced mortality (RR 0.49; 95 % CI 0.16 to 1.46; p = 0.11). Sotatercept was associated with significant improvements in 6MWD (MD 37.99 m; 95 % CI 6.47 to 69.52; p = 0.04) and WHO functional class (RR 2.04; 95 % CI 1.79 to 2.31; p = 0.002). Hemodynamic improvements included reductions in PVR (MD -237.73 dyn·s/cm5; 95 % CI -367.02 to -1.8.43; p = 0.02) and mPAP (MD -14.88 mmHg; 95 % CI -24.76 to -4.99; p = 0.02). Serious adverse events were similar (RR 0.79; 95 % CI 0.51 to 1.23; p = 0.15). CONCLUSION: Sotatercept significantly improves functional and hemodynamic outcomes in PAH, with a favorable safety profile. While mortality benefits remain uncertain, these findings support its clinical utility as an emerging therapy in PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Massachusetts Chan Medical School, Baystate Medical Center, Springfield, MA 01199, USA. Electronic address: MAbdulelah@SOM.Umaryland.Edu.
- Department of Internal Medicine, University of Massachusetts Chan Medical School, Baystate Medical Center, Springfield, MA 01199, USA.
- Department of Medicine, Sri Muthukumaran Medical College Hospital and Research Institute, Chennai, Tamil Nadu, India.
- Department of Medicine, Government Medical College Thiruvananthapuram, Kerala, India.
- Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Pulmonary and Critical Care, U Mass Chan Medical School - Baystate, USA; Department of Medicine, Duke University, USA.
Zitieren
APA
Abdulelah, M., Ezenna, C., Jenil-Franco, A., Jamouss, K. T., Krishna, M. M., Joseph, M., Chi, K. Y., & Dahhan, T. (2025). Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2025.107520
Vancouver
Abdulelah M, Ezenna C, Jenil-Franco A, Jamouss KT, Krishna MM, Joseph M, et al. Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Vascular Pharmacology. 2025. doi:10.1016/j.vph.2025.107520
BibTeX
@article{Abdulelah2025,
author = {Abdulelah, Mohammad and Ezenna, Chidubem and Jenil-Franco, Ancy and Jamouss, Kevin T and Krishna, Mrinal Murali and Joseph, Meghna and Chi, Kuan-Yu and Dahhan, Talal},
title = {Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials},
journal = {Vascular Pharmacology},
year = {2025},
doi = {10.1016/j.vph.2025.107520}
}
EUVIMED